Admin-Core-001
$225,752U54FY2022CANIH
Research Inst Nationwide Children'S Hosp, Columbus OH
Investigators
Linked publications, trials & patents
Paper 39513363Paper 39464114Paper 39266215Paper 39044819Paper 38627969Paper 38496503Paper 37868989Paper 36871221Paper 36765663Paper 36508930Paper 36483545Paper 35857488Paper 35258793Paper 35152994Paper 35105718Paper 34599026Paper 34559190Paper 34244307Paper 31828566Paper 31704085Paper 31650024Paper 31621900
Abstract
This application describes the Pediatric Ohio-New York Cancer (Peds-ONC) Immunotherapy Center, created in response to the RFA as a second nidus for the Pediatric Immunotherapy Discovery and Development Consortium (PI-DDN). To complement the funded U54 (Maris and Mackall, MPI) of the PI-DDN that largely seeks to harness adaptive immunity to further develop CAR-T cells against newly identified antigens, we propose to harness innate immunity to target pediatric cancers, to circumvent resistance to conventional therapy, and to further enable adaptive/hybrid immune approaches
View original record on NIH RePORTER →